Latest Breaking News On - திரவ பயாப்ஸி - Page 10 : comparemela.com
Genemarkers LLC & Swift Biosciences Detect Unexpected Variant from COVID-19 S Gene Dropout Samples from Kalamazoo, MI
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Genemarkers LLC & Swift Biosciences Detect Unexpected Variant from COVID-19 S Gene Dropout Samples from Kalamazoo, MI
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Genemarkers LLC & Swift Biosciences Detect Unexpected Variant from COVID-19 S Gene Dropout Samples from Kalamazoo, MI
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Micronoma, the first cancer detection biotech company that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology, today announced the closing of $3.5 million in convertible debt financing. The contributions came from existing investor, US-based SymBiosis, LLC, and new European investor, The Seerave Foundation. The investments bring Micronoma's total amount of funding to $6.5 million since the company's first seed round six months ago.
Liquid Biopsy Marks The Progression Of Colorectal Cancer by Karishma Abhishek on February 16, 2021 at 10:42 AM
Liquid biopsy assessing the blood or urine samples may help monitor the effectiveness of cancer therapy for the initial phase of colorectal cancer metastasis (oligometastatic) as per a study from Washington University School of Medicine in St. Louis, published in the Journal of Clinical Oncology Precision Oncology, a journal of the American Society of Clinical Oncology. Oligometastatic colorectal cancer requires initial chemotherapy to shrink and remove the remains of the primary tumor before having surgery. Food and Drug Administration (FDA) has approved a few liquid biopsies for lung, breast, ovarian, and prostate cancers, but none has been approved for colorectal cancer.